Generic Name: cenicriviroc

Pronunciation: N/A

Abbreviation: CVC

Other Market Name: N/A

Drug Class: NAFLD/NASH Medications

Company: Allergan

Approval Status: Experimental

Generic Version Available: No

Experimental Code: TAK-652, TBR-652

General Info

Cenicriviroc is a C-C chemokine receptor type 2 and type 5 antagonist in Phase 3 clinical trials for treatment of non-alcoholic steatohepatitis (NASH). Cenicriviroc was aquired by Allergan from Tobira Therapeutics. 


Dosing Info: N/A

Side Effects


Last Reviewed: February 4, 2019